PMID- 3284731
OWN - NLM
STAT- MEDLINE
DCOM- 19880614
LR  - 20190912
IS  - 0012-6578 (Print)
IS  - 0012-6578 (Linking)
VI  - 22
IP  - 3
DP  - 1988 Mar
TI  - Monoamine oxidase inhibitors: safety and efficacy issues.
PG  - 232-5
AB  - Controversy has historically centered on the use of monoamine oxidase inhibitors 
      (MAOI) in the treatment of depression because of safety and efficacy issues. 
      Hypertensive crisis following ingestion of foods containing tyramine is the most 
      feared problem associated with MAOI therapy. The authors conclude that only four 
      tyramine-containing foods clearly warrant absolute prohibition, but indicate 
      situations where moderation should apply. Although MAOI remain second-line agents 
      in the treatment of endogenous depression, it is unclear whether MAOI or 
      tricyclic antidepressants should be the drugs of choice in atypical depression 
      and this question necessitates future research.
FAU - Brown, C S
AU  - Brown CS
AD  - Department of Clinical Pharmacy, University of Tennessee, Memphis 38163.
FAU - Bryant, S G
AU  - Bryant SG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Drug Intell Clin Pharm
JT  - Drug intelligence & clinical pharmacy
JID - 0212457
RN  - 0 (Monoamine Oxidase Inhibitors)
SB  - IM
MH  - Depressive Disorder/drug therapy
MH  - Diet
MH  - Humans
MH  - Monoamine Oxidase Inhibitors/*adverse effects/therapeutic use
RF  - 23
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
AID - 10.1177/106002808802200311 [doi]
PST - ppublish
SO  - Drug Intell Clin Pharm. 1988 Mar;22(3):232-5. doi: 10.1177/106002808802200311.